Paul McSheehy
Overview
Explore the profile of Paul McSheehy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zanini E, Forster-Gross N, Bachmann F, Brungger A, McSheehy P, Litherland K, et al.
Front Oncol
. 2024 Aug;
14:1447807.
PMID: 39184047
Background: Threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) are common essential kinases that collaborate in activating the spindle assembly checkpoint (SAC) at the kinetochore, ensuring appropriate chromosome alignment...
2.
Braun S, McSheehy P, Litherland K, McKernan P, Forster-Gross N, Bachmann F, et al.
Expert Opin Investig Drugs
. 2021 Oct;
30(11):1071-1080.
PMID: 34698609
Introduction: This review evaluates the clinical role of fibroblast growth factor receptor 2 (FGFR2) inhibition with derazantinib in patients with intrahepatic cholangiocarcinoma (iCCA) harboring actionable oncogenic fusions/rearrangements, mutations and amplifications....
3.
Genoud V, Espinoza F, Marinari E, Rochemont V, Dietrich P, McSheehy P, et al.
JCI Insight
. 2021 Aug;
6(18).
PMID: 34403371
Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact. We hypothesized that drugs targeting mitosis might affect...
4.
Burgenske D, Talele S, Pokorny J, Mladek A, Bakken K, Carlson B, et al.
Neuro Oncol
. 2021 Jul;
24(3):384-395.
PMID: 34232318
Background: Glioblastoma (GBM) is an incurable disease with few approved therapeutic interventions. Radiation therapy (RT) and temozolomide (TMZ) remain the standards of care. The efficacy and optimal deployment schedule of...
5.
Soldermann C, Simic O, Renatus M, Erbel P, Melkko S, Wartmann M, et al.
J Med Chem
. 2020 Nov;
63(23):14576-14593.
PMID: 33252239
MALT1 plays a central role in immune cell activation by transducing NF-κB signaling, and its proteolytic activity represents a key node for therapeutic intervention. Two cycles of scaffold morphing of...
6.
Quancard J, Simic O, Soldermann C, Aichholz R, Blatter M, Renatus M, et al.
J Med Chem
. 2020 Nov;
63(23):14594-14608.
PMID: 33216547
The paracaspase MALT1 has gained increasing interest as a target for the treatment of subsets of lymphomas as well as autoimmune diseases, and there is a need for suitable compounds...
7.
Laborde L, Oz F, Ristov M, Guthy D, Sterker D, McSheehy P
Cancer Chemother Pharmacol
. 2017 Aug;
80(4):869-878.
PMID: 28779265
Purpose: Everolimus is a drug used successfully in a number of different oncology indications, but significant on-target toxicities exist. We explored the possibility of improving the therapeutic index (TI) by...
8.
Bold G, Schnell C, Furet P, McSheehy P, Bruggen J, Mestan J, et al.
J Med Chem
. 2015 Dec;
59(1):132-46.
PMID: 26629594
This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular...
9.
Traxler P, Allegrini P, Brandt R, Brueggen J, Cozens R, Fabbro D, et al.
Cancer Res
. 2004 Jul;
64(14):4931-41.
PMID: 15256466
Aberrant epidermal growth factor receptor (EGFR) and ErbB2 expression are associated with advanced disease and poor patient prognosis in many tumor types (breast, lung, ovarian, prostate, glioma, gastric, and squamous...
10.
Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin C, et al.
Clin Cancer Res
. 2003 Sep;
9(10 Pt 1):3779-87.
PMID: 14506171
Purpose: The purpose is to investigate whether STI571, through platelet-derived growth factor receptor inhibition, enhances the therapeutic response to the chemotherapeutic drug epothilone B (EPO906) and, if so, to analyze...